On September 17, 2015 Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported poster presentations at the 40th European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper)/18th European Cancer Congress being held September 25-29, 2015 at the Messe Wien Exhibition & Congress Centre in Vienna, Austria (Press release, Verastem, SEP 17, 2015, View Source;p=RssLanding&cat=news&id=2088485 [SID:1234507488]).
The details for the poster presentations at ESMO (Free ESMO Whitepaper) are as follows:
Title: FAK Inhibitor Defactinib (VS-6063) Targets Mesothelioma Cancer Stem Cells: Rationale for Maintenance Therapy after Conventional Chemotherapy
Date and time: Monday, September 28, 2015, 4:45 pm – 6:45 pm CEST
Location: Hall C; Poster #P287
Session info: Translational Research-Tumor Stem Cells
Title: VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells
Date and time: Monday, September 28, 2015, 4:45 pm – 6:45 pm CEST
Location: Hall C; Poster #P288
Session info: Translational Research-Tumor Stem Cells
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Research has demonstrated that FAK activity is critical for the growth and survival of cancer stem cells. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com), a "Window of Opportunity" study in patients with mesothelioma prior to surgery, a Phase 1/1b study in combination with paclitaxel in patients with ovarian cancer, a trial in patients with KRAS-mutated non-small cell lung cancer and a trial evaluating the combination of VS-6063 and VS-5584 in patients with relapsed mesothelioma. VS-6063 has been granted orphan drug designation for use in mesothelioma in the U.S. and EU.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
About VS-5584
VS-5584 is an orally available compound that has demonstrated potent and highly selective activity against class 1 PI3K enzymes and dual inhibitory actions against mTORC1 and mTORC2. In preclinical studies, VS-5584 has been shown to reduce the percentage of cancer stem cells and induce tumor regression in chemotherapy-resistant models. Verastem is currently conducting a dose escalation trial of VS-5584 in patients with advanced solid tumors as a single agent and a combination trial of VS-5584 and VS-6063 in patients with relapsed mesothelioma. VS-5584 has been granted orphan drug designation for use in mesothelioma in the U.S. and EU.